How long do the existing patents for ocrelizumab last?

Ocrelizumab's composition-of-matter patent (U.S. 7,682,612) expires in 2024. This core protection covers the antibody itself and is the main barrier to biosimilar entry. Additional patents on manufacturing processes, formulations, and methods of use extend through 2028–2032, but these narrower claims are easier to design around.

When does the main patent on ocrelizumab expire?
The key composition-of-matter patent ends in March 2024. After that date, any company may seek FDA approval for a biosimilar version, though remaining process and use patents may still require separate legal challenges or licensing.

How do secondary patents affect biosimilar timelines?
Process patents filed later (2028–2032) protect specific cell-culture methods and stable liquid formulations. Biosimilar developers have already filed patent challenges against these secondary patents; outcomes will determine whether full market entry occurs in 2024 or is delayed until the late 2020s.

Can biosimilars reach the U.S. market before 2028?
Several companies have announced development programs and are targeting launch windows in 2025–2027. Success depends on prevailing in inter partes review proceedings and on any settlement agreements with the originator. Early entry would require either patent invalidation or negotiated licenses.

Why are companies challenging these patents?
Biosimilar firms argue that some manufacturing patents are obvious extensions of known antibody production techniques. If the Patent Trial and Appeal Board invalidates the claims, the effective exclusivity period for ocrelizumab shortens, opening the market sooner and lowering treatment costs.

What happens to pricing when patents expire?
List prices for ocrelizumab currently exceed $65,000 per year. Historical data on other monoclonal antibodies show average price reductions of 30–50 % within the first two years after biosimilar launch. Actual savings will vary by payer contracts and state substitution laws.

Who makes the original ocrelizumab product?
Genentech, a Roche subsidiary, holds the original biologics license and markets the drug as Ocrevus. The company has publicly stated it will defend its remaining patents through litigation and potential authorized biosimilar partnerships.

[1] DrugPatentWatch.com